Cartesian Therapeutics (RNAC) Intangibles (2023 - 2026)

Cartesian Therapeutics (RNAC) has 4 years of Intangibles data on file, last reported at $93.9 million in Q1 2026.

• On a quarterly basis, Intangibles fell 37.65% year-over-year to $93.9 million in Q1 2026; TTM through Mar 2026 was $93.9 million, a 37.65% decrease from a year earlier, with the FY2025 full-year figure at $93.9 million, down 37.65% from the prior year.
• Intangibles for Q1 2026 stood at $93.9 million, roughly flat from $93.9 million in the prior quarter.
• Over the last five years, Intangibles for RNAC reached as high as $150.6 million in Q4 2023 and fell as low as $93.9 million in Q4 2025.
• Historically, Intangibles has averaged $139.3 million across 4 years, with a median of $150.6 million in 2023.
• Across the five-year window, Intangibles changed 0.0% in 2024 and sank 37.65% in 2025, its largest moves.
• Year by year, Intangibles stood at $150.6 million in 2023, then changed by 0.0% to $150.6 million in 2024, then sank by 37.65% to $93.9 million in 2025, then changed by 0.0% to $93.9 million in 2026.
• Per Business Quant data, the three most recent Intangibles figures were $93.9 million in Q1 2026, $93.9 million in Q4 2025, and $150.6 million in Q3 2025.